Sun Pharma Launches Semaglutide Injections Noveltreat and Sematrinity
Filing Summary
Sun Pharmaceutical Industries Ltd has launched its semaglutide injections under the brand names Noveltreat and Sematrinity in India. Noveltreat is intended for chronic weight management and is available in five dose strengths, while Sematrinity targets type 2 diabetes mellitus with two dose strengths. The pricing for Noveltreat ranges from ₹900 to ₹2,000, and for Sematrinity from ₹750 to ₹1,300. These products are designed to be more affordable than the innovator brand. The launch includes a patient support program to assist users throughout their treatment.
Sun Pharmaceutical Industries Limited has announced the launch of its semaglutide injection products under the brand names Noveltreat and Sematrinity in India. Noveltreat is indicated for chronic weight management in adults, while Sematrinity is intended for the treatment of adults with insufficiently controlled type 2 diabetes mellitus. Both products are available in multiple dose strengths to cater to varying patient needs.
The pricing strategy for these products positions them as more affordable alternatives to the innovator brand. The weekly therapy costs for Noveltreat range from approximately ₹900 to ₹2,000, depending on the dose strength. For Sematrinity, the costs range from ₹750 to ₹1,300. This pricing approach is aimed at enhancing affordability for a broader patient base in India.
Noveltreat is available in five dose strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. Sematrinity is offered in two dose strengths: 2 mg/1.5 mL and 4 mg/3 mL. Noveltreat’s prefilled pen features a concealed needle to improve handling safety and dosing accuracy. Sematrinity is provided in a multi-dose pen format with a smooth dialer for flexible and accurate dose delivery. These devices are manufactured in Europe by leading global pharmaceutical device suppliers.
The launch of these products is accompanied by a holistic patient support program. This program is designed to guide patients throughout their treatment journey, providing additional support and resources. The introduction of these products aligns with Sun Pharma’s strategy to offer high-quality, affordable therapies to a wider patient community in India.
Sun Pharmaceutical Industries Limited is the world’s leading specialty generics company, with a significant presence in innovative medicines, generics, and consumer healthcare products. It is the largest pharmaceutical company in India and a leading generic company in the US and global emerging markets. Sun Pharma’s operations are vertically integrated, delivering high-quality medicines trusted by physicians and consumers in over 100 countries.